
Here are some gene therapy delivery methods. This page deals mainly with transfection and delivery, whereas [[gene-editing]] pertains to the mechanisms of changing the genetic material, which is what gene therapy endeavors to deliver into cells. See also [[cell therapy]].

# naked DNA

# direct mRNA exposure

[Foliar mRNA spray induces protein synthesis in monocot crop and dicot model plant species](https://www.biorxiv.org/content/10.1101/2025.08.07.668951v1)

# nasal

[New intranasal and injectable gene therapy for healthy life extension](https://www.biorxiv.org/content/10.1101/2021.06.26.449305v1)

# hydrodynamic injection

# viruses and viral gene therapy

* [CAV-2 - why a canine virus is a neurobiologist's best friend](http://easco.org/home/sites/default/files/files_rep/pdf/CAV2why%20a%20canine%20virus.pdf)
* AAV
* lentiviral
* rabies virus, as used in neuroscience work

[Epigenetic landscape and AAV targeting of human neocortical cell classes](https://www.biorxiv.org/content/10.1101/555318v1)

[Generation of viral vectors specific to neuronal subtypes of targeted brain regions by Enhancer-Driven Gene Expression (EDGE)](https://www.biorxiv.org/content/10.1101/606467v1.supplementary-material)

[Systematic multi-trait AAV capsid engineering for efficient gene delivery](https://www.biorxiv.org/content/10.1101/2022.12.22.521680v1)

# electroporation

[An efficient electroporation protocol for the genetic modification of mammalian cells](http://biorxiv.org/content/early/2016/09/04/073387) (2016)

# gene gun

# sonoporation

# gas-filled micro-bubbles

# magnetofection and magnetic nanoparticles

* magnetic calcium phosphate nano-formulations

# carbon nanotubes

# quantum dots

* super paramagnetic iron oxide nanoparticles (SPIONS)

# lipoplexes

# dendrimers

# inorganic nanoparticles

* carbon nanotuubes
* magnetic nanoparticles (see also magnetofection)
* calcium phosphate nanoparticles
* gold nanoparticles
* quantum dots
* C60 fullerenes
* aminofullerenes
* silica nanoparticles

# gold nanoparticles

# cell-penetrating peptides

# polymerosomes

# liposomes

# polyplexes (DNA + plastic)

* polyion complex micelles (PICs)

# cationic polymers

* collagen
* albumin
* beta-casein
* zein

# cationic lipids

* dioleylpropyl trimethylammonium chloride (DOTMA)
* dioleoyl trimethylammonium propane (DOTAP)

# cationic emulsions

# solid lipid nanoparticles

# virosomes

# protofection

# natural competence

# Ligandal's nano-gobstopper method

(patent) [Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations](https://patents.google.com/patent/CA2924535A1)

conjugation of PEI for DNA binding, histone tail peptide for nuclear localization, poly-glutamic acid, glutamic acid for stabilization and charge balancing or whatever, then you stick DNA to it, and silica coat the whole thing, then add even more cell-targeting stuff to the outside.

# other

* poly lactic-co-glycolic acid (PLGA)-based nanoparticles
* hybrid nanoparticles such as liposome-polycation-DNA (LPD) nanoparticles
* lipopolyplexes
* [Minicircle Inc follistatin gene therapy doesn't work](https://docs.google.com/document/d/e/2PACX-1vT7_6kWkIqrvzFZvs88O_NqVzmn-NPINvHOLM-A6r_ieZyvnJsNVk4FSU7EYrePnQg9gT_3kwahJESZ/pub)
* direct delivery of cas9 protein instead of genetically encoded cas9 editors: [Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins](https://www.nature.com/articles/s41467-025-63167-x)
* [Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids](https://www.biorxiv.org/content/10.1101/538421v1) (2019)
* brain intraparenchymal injection for the delivery of AAV gene therapy into brain ([ref](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940433/)), we should also consider direct intraparenchymal injection for cell therapy as well.

# cell therapy

[[!inline  pagenames="cell_therapy"  raw="yes"]]

# hplusroadmap logs

See <http://gnusha.org/logs/2017-01-09.log> for some preliminary stuff.

# Physical (non-viral) delivery

* **Electroporation (in vivo / “gene electrotransfer”)** — robust local transfection of muscle, skin, liver and tumors; active clinical exploration in oncology and vaccines; tunable pulse parameters determine efficacy/toxicity. Reviews and recent data: Hensley *et al.* 2024; Hughes & Kandarian 2022; Conniff *et al.* 2024. [MDPI](https://www.mdpi.com/2076-3417/14/23/11298?utm_source=chatgpt.com), [Physiological Journals](https://journals.physiology.org/doi/abs/10.1152/japplphysiol.00088.2022?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11304878/?utm_source=chatgpt.com)
* **In utero electroporation (IUE)** — staple for CNS development and fetal gene transfer in rodents; efficient neuronal targeting; still preclinical. Classics & updates: Taniguchi *et al.* 2011; Maeda *et al.* 2024. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3530425/?utm_source=chatgpt.com), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0012160624002069?utm_source=chatgpt.com)
* **In vivo electroporation (general/overviews)** — broad reviews of electroporation, sonoporation, magnetoporation, optoporation and related physical methods. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6058615/?utm_source=chatgpt.com)
* **Microinjection (zygote/embryo)** — used in germline or embryo editing; widely used for CRISPR and prime editing. Recent examples: two-cell microinjection boosts prime editing (2024); zygote microinjection with CRISPR post-vitrification (2024). Cellular microinjection can deliver chemicals and genetic material into the cell. [Nature](https://www.nature.com/articles/s41587-023-02106-x?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232997/?utm_source=chatgpt.com)
* **Hydrodynamic injection (tail-vein & limb-vein)** — rapid, large-volume injections give high hepatocyte (and limb muscle) transfection; standard in small animals; clinical translation via lobe-specific/isolated perfusion is being explored. Reviews, protocols, and variants: Suda *et al.* 2023; Wen *et al.* 2024; Hegge *et al.* 2010; STAR Protocols 2025. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10141091/?utm_source=chatgpt.com), [STAR Protocols](https://star-protocols.cell.com/protocols/4187?utm_source=chatgpt.com)
* **Ultrasound-mediated transfection (sonoporation)** — ultrasound + microbubbles transiently permeabilize membranes and can open the BBB (FUS-BBBO) to deliver genes or AAV to brain; active preclinical & early clinical work. Reviews/mechanism and AAV+FUS studies: Du *et al.* 2022; Wang *et al.* 2024 (AAV to brain); Kofoed *et al.* 2024; Blesa *et al.* 2023. [Frontiers](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.803055/full?utm_source=chatgpt.com), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0169409X24001856?utm_source=chatgpt.com), [Cell](https://www.cell.com/trends/molecular-medicine/abstract/S1471-4914%2823%2900285-X?utm_source=chatgpt.com), [Science](https://www.science.org/doi/10.1126/sciadv.adf4888?utm_source=chatgpt.com)

# Viral vectors

* **AAV gene therapy** — capsid engineering, payload limits, immunogenicity & re-dosing challenges; multiple approvals and intense innovation. Strong 2024–2025 reviews: Wang *et al.* 2024 (Signal Transduct Target Ther); Zwi-Dantsis & Rashid 2025; Ling *et al.* 2023 (neuro). [Nature](https://www.nature.com/articles/s41392-024-01780-w?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11861813/?utm_source=chatgpt.com), [PubMed](https://pubmed.ncbi.nlm.nih.gov/37658167/?utm_source=chatgpt.com)
* (For breadth: Bulcha *et al.* 2021 review of **AAV/Lenti/Adenovirus** platforms.) [Nature](https://www.nature.com/articles/s41392-021-00487-6?utm_source=chatgpt.com)

# Non-viral chemical vectors

* **Lipid nanoparticles (LNPs)** — clinically validated (mRNA vaccines); active work on targeting and **endo/lysosomal escape**. Key reviews spanning fundamentals→frontier: Hou *et al.* 2021; Chatterjee *et al.* 2024 (PNAS, endosomal escape bottleneck); Wang *et al.* 2025 (endo/lysosomal-escapable LNP design); Brimacombe *et al.* 2025 (gene-therapy LNP design). [Nature](https://www.nature.com/articles/s41578-021-00358-0?utm_source=chatgpt.com), [PNAS](https://www.pnas.org/doi/10.1073/pnas.2307800120?utm_source=chatgpt.com), [MDPI](https://www.mdpi.com/1999-4923/17/7/803?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274843/?utm_source=chatgpt.com)
* **Polymers / polyplexes & hybrids** — PAMAM/PEI/PBAE, polymer–lipid hybrids; ongoing advances in targeting & intracellular trafficking. Good overviews 2023–2025. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11435517/?utm_source=chatgpt.com), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0168365924008459?utm_source=chatgpt.com)
* **Nanoparticle “lysosome angle” (why it matters)** — many vectors are endocytosed and risk degradation in **lysosomes**, so endosomal escape is pivotal; reviews on mechanisms & strategies (2023–2025). [Science Advances](https://spj.science.org/doi/10.34133/research.0148?utm_source=chatgpt.com), [ACS Publications](https://pubs.acs.org/doi/10.1021/acs.langmuir.4c05176?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11243486/?utm_source=chatgpt.com)

# “Bleeding-edge” & hybrid systems

* **Focused ultrasound to deliver AAV/genes across BBB** — noninvasive, spatially targeted; rapid progress toward clinical translation. Recent method & engineering papers. [Nature](https://www.nature.com/articles/s41467-024-48974-y?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105982/?utm_source=chatgpt.com)
* **Virus-like particles (VLPs) for CRISPR RNPs** — transient, non-integrating protein delivery with viral entry efficiency; now programmable for tropism. Nature Nano 2025; Mol Ther-Nucleic Acids 2025; proof-of-concept cancer models (2023). [Nature](https://www.nature.com/articles/s41565-024-01851-7?utm_source=chatgpt.com), [Cell](https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531%2825%2900011-3?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10192467/?utm_source=chatgpt.com)
* **Extracellular vesicles / exosomes** — biologically derived carriers for mRNA/siRNA/CRISPR cargo; active engineering for loading, targeting & endosomal escape. Recent reviews & examples (2024–2025). [Nature](https://www.nature.com/articles/s12276-024-01201-6?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225225/?utm_source=chatgpt.com)

# Reviews that each cover multiple modalities

* **Molecular Therapy—Nucleic Acids (2025):** “Advanced delivery systems for gene editing” (viral, non-viral, VLPs; preclinical→clinical). [Cell](https://www.cell.com/molecular-therapy-family/nucleic-acids/pdf/S2162-2531%2825%2900011-3.pdf?utm_source=chatgpt.com)
* **AIP Appl. Phys. Rev. (2025):** in-vivo delivery systems for CRISPR (AAV, LNP, others). [AIP Publishing](https://pubs.aip.org/aip/apr/article/12/2/021319/3347618/In-vivo-delivery-systems-for-CRISPR-genome-editing?utm_source=chatgpt.com)
* **MDPI Int. J. Mol. Sci. (2024):** Viral and non-viral systems to deliver gene-editing therapeutics (broad survey). [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/?utm_source=chatgpt.com)
* **J Nanobiotechnology (2023):** comprehensive non-viral vectors (LNPs, dendrimers, polymers, etc.). [BioMed Central](https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-023-02044-5?utm_source=chatgpt.com)
* **Advanced Drug Delivery Reviews (topic collection, 2023):** multiple articles on intracellular barriers and escape. [ScienceDirect](https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/200/suppl/C?utm_source=chatgpt.com)

---

## Notes

* **Electroporation / in vivo / in utero:** IUE is excellent for CNS developmental studies and fetal targeting (rodents). [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3530425/?utm_source=chatgpt.com), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0012160624002069?utm_source=chatgpt.com)
* **Microinjection:** one of the methods for embryo/zygote editing (CRISPR, base/prime editing). It's not the only method of embryo engineering. [Nature](https://www.nature.com/articles/s41587-023-02106-x?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232997/?utm_source=chatgpt.com)
* **Hydrodynamic injection:** liver-dominant transfection; clinical strategies focus on lobe-specific or isolated-organ approaches to reduce cardiovascular load. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10141091/?utm_source=chatgpt.com)
* **Ultrasound transfection:** sonoporation in peripheral tissues and **FUS-BBBO** in brain; multiple comparisons and mechanism papers. [Frontiers](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.803055/full?utm_source=chatgpt.com), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0169409X24001856?utm_source=chatgpt.com)
* **AAV gene therapy:** best-documented clinical track record; capsid engineering, tropism, immunogenicity & manufacturing are the hot spots. [Nature](https://www.nature.com/articles/s41392-024-01780-w?utm_source=chatgpt.com)
* **Lysosomes:** for nanoparticle/LNP delivery, endo/lysosomal trafficking is a bottleneck; modern designs explicitly seek endosomal escape or lysosome-avoidance. [PNAS](https://www.pnas.org/doi/10.1073/pnas.2307800120?utm_source=chatgpt.com), [MDPI](https://www.mdpi.com/1999-4923/17/7/803?utm_source=chatgpt.com)
* **Lipid nanoparticles:** clinically proven for RNA; expanding to DNA and gene editors with active control over trafficking & release. [Nature](https://www.nature.com/articles/s41578-021-00358-0?utm_source=chatgpt.com)

---

## Bibliography

* **Physical methods overview:** Du *et al.* 2018; Mellott *et al.* 2012. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6058615/?utm_source=chatgpt.com)
* **Electroporation in vivo:** Hensley *et al.* 2024; Conniff *et al.* 2024. [MDPI](https://www.mdpi.com/2076-3417/14/23/11298?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11304878/?utm_source=chatgpt.com)
* **IUE basics & update:** Taniguchi *et al.* 2011; Maeda *et al.* 2024. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3530425/?utm_source=chatgpt.com), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0012160624002069?utm_source=chatgpt.com)
* **Hydrodynamic delivery:** Suda *et al.* 2023; Wen *et al.* 2024. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10141091/?utm_source=chatgpt.com)
* **Ultrasound/sonoporation:** Du *et al.* 2022; Ye *et al.* 2024 (AAV+FUS to brain). [Frontiers](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.803055/full?utm_source=chatgpt.com), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0169409X24001856?utm_source=chatgpt.com)
* **AAV reviews:** Wang *et al.* 2024; Zwi-Dantsis & Rashid 2025. [Nature](https://www.nature.com/articles/s41392-024-01780-w?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11861813/?utm_source=chatgpt.com)
* **LNPs & endosomal escape:** Hou *et al.* 2021; Chatterjee *et al.* 2024; Wang *et al.* 2025. [Nature](https://www.nature.com/articles/s41578-021-00358-0?utm_source=chatgpt.com), [PNAS](https://www.pnas.org/doi/10.1073/pnas.2307800120?utm_source=chatgpt.com), [MDPI](https://www.mdpi.com/1999-4923/17/7/803?utm_source=chatgpt.com)
* **Broad “all-methods” reviews:** Cavazza *et al.* 2025; Taghdiri *et al.* 2024; Wang *et al.* 2023 (non-viral vectors). [Cell](https://www.cell.com/molecular-therapy-family/nucleic-acids/pdf/S2162-2531%2825%2900011-3.pdf?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/?utm_source=chatgpt.com), [BioMed Central](https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-023-02044-5?utm_source=chatgpt.com)
* **VLPs for CRISPR:** Ling *et al.* 2025; Hu *et al.* 2023. [Nature](https://www.nature.com/articles/s41565-024-01851-7?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10192467/?utm_source=chatgpt.com)
* **EVs/exosomes for nucleic acids:** Kim *et al.* 2024; Iqbal *et al.* 2024. [Nature](https://www.nature.com/articles/s12276-024-01201-6?utm_source=chatgpt.com), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225225/?utm_source=chatgpt.com)



